It is probable that all anti-hypertensive drugs are associated with some reduction in left ventricular wall thickness and this effect is predominantly related to the fall in blood pressure. There is evidence, however, that the angiotensin-converting enzyme (ACE) inhibitors bring about a greater reduction in left ventricular posterior wall thickness and interventricular-septal thickness than the other classes of blood pressure lowering drugs. [1] [2] [3] This increased efficacy of ACE inhibition has led many to suggest that angiotensin II is itself involved in the initial development of left ventricular hypertrophy (LVH). 4 Indeed, angiotensin is a potent trophic factor which influences cardiac structure through actions on myocytes and fibroblasts, in addition to coronary artery smooth muscle cells and endothelial cells. 5, 6 Since the advent of angiotensin receptor antagonists in clinical practice, there has been great interest in the potential differences between the effects of blocking the renin-angiotensin system at the level of the ACE or blocking the system at the AT1 receptor. The AT1 receptor antagonists appear comprehensively to block the receptors, but have no effects on the bradykinin/kinin system. Conversely, the ACE inhibitors do not completely block the generation of angiotensin II, as its formation continues via non-ACE pathways, such as the cardiac chymase system. 7 The tissue levels of angiotensin, therefore, appear to vary widely following the administration of an ACE inhibitor. 8 However, ACE inhibitors do affect the bradykinin/kinin system and although the potentiation of kinins may have important beneficial effects on LVH regression, 9 there are the adverse effects of cough and angioedema.
Meanwhile, the ACE inhibitors have been shown to have beneficial effects on the kidney and the retina, as well as clotting factors, [10] [11] [12] [13] and these appear to be largely unrelated to their effects on blood Correspondence: CR Gibbs, Department of Medicine, City Hospital, Dudley Road, Birminghamm B18 7QH, UK pressure. The question really arises as to whether the angiotensin receptor antagonists will have similarly beneficial effects. Preliminary work suggests that these drugs do reduce proteinuria 14 and several long-term outcome studies are currently underway to investigate the effect of angiotensin receptor antagonists on renal function, in both diabetic and non-diabetic nephropathy. Turning to the heart, experimental cardiac models have demonstrated that AT1 receptor antagonists are associated with beneficial effects on cardiac structure. For example, losartan in animal models prevents angiotensin IIinduced cardiac hypertrophy, attenuates the development of LVH and promotes LVH regression. [15] [16] [17] In other animal studies losartan has been shown to reduce cardiac hypertrophy and fibrosis, as well as vascular hypertrophy, improve coronary blood flow, prevent post-infarction cardiac remodelling and reduce mortality in hypertensive rat models. [18] [19] [20] [21] The early echocardiographic studies of AT1 receptor antagonists and LVH regression have largely been encouraging, but not all have yet been published in peer-reviewed journals. [22] [23] [24] [25] [26] [27] [28] However, two studies stand out as providing surprising results. The study by Himmelmann and co-workers, published in this journal in 1996, suggested that losartan may lead to an increase in left ventricular wall thickness in people with marked cardiomegaly. 27 However, this was a small open-label study and was a little difficult to interpret owing to complexities of the drug regime. More recently Cheung published a study of changes in left ventricular wall thickness, in response to treatment with losartan, in people with normal or only very slightly enlarged ventricles. 28 This study also suggested a statistically significant increase in left ventricular wall mass, although the study was also small, the follow-up was short and critics would comment that the reported change was within measurement error. Both studies are therefore open to some criticism.
However, echocardiographic studies should be treated with immense caution, as Dahlof and Devereux have rightly drawn attention to the many pitfalls with this technique. 29 In the assessment of drug-related changes in left ventricular mass, studies should be randomised, double-blinded and performed over a period of at least 6 months. 29 In general, cardiologists have been more aware of the frailty of echocardiography, than non-cardiac specialists with little personal experience of the technique.
The situation may be resolved by the publication in the present issue of the Journal of Human Hypertension of a study by Tedesco and co-workers. 30 This reports a highly significant reduction in left ventricular mass, in a long-term randomised doubleblind study of 42 patients treated with losartan 50 mg daily. Left ventricular mass was reduced at 10 months and at 22 months, with reductions in posterior wall and interventricular-septal thickness. A smaller effect was observed in patients treated with hydrochlorthiazide, although this did not attain statistical significance. The number of patients studied and the duration of the study by Tadesco are largely reassuring, and these results certainly seem more credible. It must be intrinsically unlikely that blocking the renin system at the angiotensin receptor would have adverse effects on LVH, when all other anti-hypertensive drugs appear to be beneficial and blocking the renin system at the converting enzyme level appears to offer additional benefit. These findings are also in keeping with the beneficial effects of losartan in heart failure which were seen in the Evaluation of Losartan in the Elderly (ELITE) study, where the survival in patients taking losartan was slightly, but significantly, better than in patients treated with high-dose captopril. 31 The situation is probably, therefore, resolved and the question mark over losartan can be removed. However, the effects of losartan on other pathophysiological processes which are associated with LVH, such as impaired coronary reserve, ventricular arrhythmias, altered myocardial contractility, impaired diastolic dysfunction and the hypercoagulable state remain to be established. Long-term international randomised controlled studies, such as the Losartan Intervention for Endpoint reduction (LIFE) in hypertension study 32 are presently in progress and will answer some of these outstanding questions. In the meantime, publication of the full peerreviewed papers of the studies presented at the International Symposium on Angiotensin II Receptor Antagonism in London, on 28 September 1997, are eagerly awaited.
